

Working Group 3:

**How to establish communication
between Enpr-EMA networks and
industry**

Working Group 5:

**Sharing Good Practice within Enpr-EMA
and with Industry Partners**

Susan Tansey

Acting Chair WG 3 and WG 5

Enpr-EMA WG 3

Role:

Develop recommendations for how Enpr-EMA can:

- facilitate communication between industry and networks
- provide industry with easy access to information about capacities of individual Enpr-EMA networks
- increase the visibility of individual networks
- make contact with a range of industry partners (big Pharma, SMEs, biotechs, CROs etc).

Enpr-EMA WG 5

Role:

- Gather examples of network involvement in good practice for the development and implementation of clinical trials in children and young people
- Gather examples of good practice from industry colleagues working with Enpr-EMA networks
- Develop proposals to disseminate examples of good practice to Enpr-EMA members and industry partners.

Enpr-EMA WG 3 and WG 5

Following discussion at the first meeting of WG 5 it was decided to propose merging the two WGs for the reasons below:

- many of the members of WG 5 are also in WG 3**
- the remit was similar and it was felt that sending out a survey would be the best way to get some initial information on both examples of best practice (WG 5) but also on the current communication status between networks and industry (WG 3)**

Enpr-EMA WG 3 and WG 5

Industry members:

Ron Portman
Charles A Thompson
Matthew McClure
Martine Dehlinger-Kremer
Klaus Hartmann
Lynda Wight

Network members:

Susan Tansey (Acting Chair)
Pirkko Lepola (Steering group)
Jenny Preston (Steering group)
Pamela Dicks (Steering group)
Nicola Ruperto
Andy Pearson
Christina Peters
Richard Trompeter

Enpr-EMA WGs 3 and 5

Key Tasks, Timeframes and Outputs (1)

Progress so far

Draft questions for a survey monkey style questionnaire to collect good practice examples from both network members and Industry colleagues. Planned date: end of September 2013

Actual date: 9th December 2013

Finalise survey monkey questionnaire and distribute.

Planned date: mid-October 2013

Actual date: 18th December 2013

Deadline for responses.

Planned date: end of November 2013

Actual date: 13th January 2014

Proposed extended date: 14th February 2014

Enpr-EMA WGs 3 and 5

Key Tasks, Timeframes and Outputs (2)

Next steps

Organise teleconference to discuss and summarise responses.

Planned date: week commencing 2nd December 2013

Revised planned date: 3rd/4th March 2014

Send draft report of survey monkey to EnprEMA.

Planned date: week commencing 9th December 2013

Revised planned date: 30th March 2014

Develop a dissemination strategy to distribute and share good practice. Some ideas would include distributing via newsletters, EnprEMA website, Meeting Presentations, Webinars.

Planned date: January 2013

Revised planned date: April 2014


Initial results of Industry and Network surveys

Responses received: Total 45

Industry responses (27):


CROs : PRA, Quintiles, Covance, INC, Premier Research and Illingworth

Pharmaceutical/Biotechs: BMS (5), Astra Zeneca(3), Novartis (3), Janssen(2), Aegerion, Alios, Bayer (2), Kowa Research, Mitsubishi, Proveca and Vertex.




Initial results of Industry survey

Does your company have a paediatric council/committee?




Does your company have experience of trials in children?




Initial results of Industry survey



Are you aware of the European Network of Paediatric Research Networks within the EMA (Enpr-EMA)?




Have you, or your company worked with a research network (Enpr-EMA) or other network in the development and/or implementation of clinical trials with children?




Initial results of Network survey




Initial results of Network survey



Initial results of Network survey



Initial results of Network survey



Summary

Next steps:

- Extend deadline for survey
- Full analysis of surveys
- Draft report to EnprEMA
- Dissemination strategy for best practice examples
- Communication strategy